At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 355 enrolled
Drug / intervention
tildrakizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blinded, Placebo-Controlled, Parallel-Design, Dose-Range Finding Study of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Study P05495)
In Brief
A Phase 2 clinical trial evaluating tildrakizumab and Placebo for Psoriasis. Completed, enrolled 355 participants.
Detailed Summary
This is a response-driven study of tildrakuzumab for the treatment of moderate to severe chronic plaque psoriasis. The primary study hypothesis is that one or more doses of tildrakizumab will be superior to placebo for the treatment of psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedOct 2010
Enrollment StartOct 2010
Primary CompletionNov 2011
Study CompletionOct 2012
TodayJul 2026
First PostedOct 21, 2010
Enrollment StartOct 25, 2010
Primary CompletionNov 4, 2011
Study CompletionOct 24, 2012
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 15.7 years ago
Interventions
tildrakizumabbiological
SC administration of tildrakizumab at assigned dose
Placebodrug
SC administration of Placebo